Profusa (NASDAQ:PFSA) Upgraded by Wall Street Zen to “Sell” Rating

Profusa (NASDAQ:PFSA) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Profusa Trading Up 7.0%

NASDAQ:PFSA opened at $0.69 on Friday. Profusa has a 52 week low of $0.41 and a 52 week high of $180.00. The company has a market capitalization of $941,120.00, a price-to-earnings ratio of 0.00 and a beta of 0.28. The business’s 50-day simple moving average is $1.15.

Profusa (NASDAQ:PFSA) last released its quarterly earnings results on Wednesday, April 15th. The company reported $89.25 EPS for the quarter.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.